Financial Statements
for the 3rd quarter of fiscal year ending March 31, 2022
(From Apr. 1, 2021 to Dec. 31, 2021)

Summary of consolidated results

JMS Co., Ltd.
Company Code No. 7702

February 8, 2022
1

Highlights in Business Results(unit: JPY million)
Apr. - Dec. 2020
Results

Apr. - Dec. 2021
Results

Year-over-YearDiff.

Net sales

42,74943,769

1,019

2.4%

Operating profit

1,673

1,220(452)(27.1)%

Ordinary profit

1,565

1,233(332)(21.2)%

Profit attributable toowners of parent

1,427883(543)(38.1)%

JPY 58.47

JPY 36.17------

Basic earnings per share
Exchange Rate(averageduring period)

US Dollar

JPY 106.11

JPY 111.10

Euro

JPY 120.90

JPY 129.83(unit: JPY)

Singapore Dollar

JPY 77.03

JPY 82.46

Overseas• Continued stagnation of demand for products affected by
COVID-19• Decreased sales of Apheresis kits and Blood bags

ProfitJapanSales• Recovery trend from the effects of COVID-19• Increased sales of enteral nutrition-related products under
ISO standards and Blood Purification Tubing Sets

Increased in sales
Decreased in profit• Operating profit decreased due to higher cost of sales
ratio caused by the appreciation of local currencies inoverseas production bases, increased cost of raw material,and increased ocean freight rates• Net income decreased due to subsidy income as
extraordinary income recorded in the same quarter of theprevious year2

Summary by segment (geographical area)Japan
30,14228,15932,031

Singapore■ Sales incl.
internal transaction■ Sales for third party－ Profit

15,18013,02030,042
909

641

Sales
Increase of
6.3%

8,312
633

ProfitIncrease of
41.7%

Apr. - Dec.
2020

Apr. - Dec.
2021

[Sales]• Recovery trend from the effects of COVID-19• Increase in sales of medical gloves, enteral nutritionrelated products, Closed Drug Mixing/Infusion System“NEO SHIELD”, and hemodialysis machines to China[Ordinary profit](unit: JPY million)

Despite the increase in expenses accompanying thetransfer of the blood purification business, increase insales resulted in profit growth■ Sales incl.
internal transaction■ Sales for third party－ Profit

2,544
2,226

Sales
Decrease of14.2%

6,730
41

Apr. - Dec.
2020

China

1,338
1,063249Profit
Decrease of93.5%

Apr. - Dec.
2021

[Sales]• Decrease in Number of Blood Donors in BloodBusiness• Decrease in sales of Apheresis kits and blood bags

[Ordinary profit] Despite the decreased labor costs

and selling costs, the influence of decreased sales andthe impact of higher cost of sales ratio caused byincreased raw material cost and the appreciation oflocal currency reduced profit*This segment includes Indonesia subsidiary■ Sales incl.
internal transaction■ Sales for third party－ Profit

Apr. - Dec.
2020

108

Sales
Increase of14.3%Profit
Decrease of56.5%

Apr. - Dec.
2021

[Sales]• Number of dialysis patients in Chinese market on therise• Increase in sales of AV Fistula Needle andHemodialysis Blood Tubing Sets
• Increased sales of Blood Purification Circuit for theJapan market[Ordinary profit] Higher cost of sales ratio caused byincreased cost of raw material, and an increase in labor costs
compared to the same quarter of the previous fiscal year
when there was a reduction or exemption of social insurance
premiums resulted in a reduced profit

3

Summary by segment (geographical area)
Philippines
2,429
2,143

Germany■ Sales incl.
internal transaction■ Sales for third party－ Profit

224

2,643
2,293

129

Apr. - Dec.
2020

Apr. - Dec.
2021

2,639

2,921

Apr. - Dec.
2020
[Sales][Ordinary profit][Ordinary profit]

3,009
Sales
Increase of
3.0%

87129
ProfitDecrease of
18.9%[Sales]

The influence of increased sales resulted in an
improved profit■ Sales for third party－ Profit

Sales
Increase of
15.3%

ProfitIncrease of
191.3%• Improvement of effect from COVID-19 in the samequarter of the previous year• Increase in AV Fistula Needle for Europe raised netsales

Others■ Sales incl.
internal transaction■ Sales for third party－ Profit

2,280

Sales
Increase of13.3%

15977(unit: JPY million)

Apr. - Dec.
2021

• Increased market share of AV Fistula Needle resultedin net sales growth16
Apr. - Dec.
2020

ProfitDecrease of81.5%

Apr. - Dec.
2021

* This segment includes business activity of domestic
subsidiaries, United States, South Korea and Thailand.

Despite the effect of increased sales, an increase inpurchase costs caused by soaring marinetransportation costs resulted in a reduced profit.

4

Sales by Business Segment
Apr. – Dec. 2020

Apr. – Dec. 2021
Others 2.1%

Transfusion
16.7%
Cardiovascular
8.9%
16,724

Apr. – Dec.
2021

Infusion & Nutrition
40.6%

Sales composition

17,772
Dialysis
31.7%

13,566 13,853(unit: JPY million)
8,465

3,084

7,301

3,900
909

Infusion & Nutrition

Dialysis

CardiovascularTransfusion

941

Others5

Sales increase or decrease (Customer's Location)
Others2.0%

Europe10.4%
North America
7.5%
Asia
14.1%

Apr. – Dec.
2021

Japan66.0%

Sales composition(unit: JPY million)

Net
sales

Apr. - Dec. 2020

Increased
JPY 1,019 million

JapanAsia

North AmericaEurope

OthersNet
sales

Apr. - Dec. 2021
6Selling, General and Admin. Expenses(unit: JPY million)

9,648(unit: JPY million)
Apr. - Dec.
2021

Labor Cost

4,265

4,392

127

3.0%

Transport

1,324

1,399

75

5.7%

R&D

1,156

1,089(67)(5.9)%

252277

25

10.0%

2,649

2,637(11)(0.4)%

9,648

9,796

148

1.5%

9,796

SGA ratio (0.2)%

Depreciation
22.6%

22.4%

Others
Total

Apr. - Dec.
2020

Year-overYear

Apr. - Dec.
2020

Diff.

Apr. - Dec.
2021

7

Ordinary profit : Compared with the previous year

Decrease of
Gross Profit

Increase ofSGA

Decrease of
Non-operating
profitImpact of
Exchange rate

(unit: JPY million)

Ordinary
profitDecreased
JPY 332 million

Ordinary
profitThe underlined figures exclude impact of exchange rate.

Apr. - Dec. 2020

Apr. – Dec. 2021
8

Forecast for FYE Mar. 2022
(unit: JPY million)FYE Mar. 2021
ResultFYE Mar. 2022
Forecast

Year-over-Year

Net sales

57,57858,0000.7%Operating profit

2,127

1,200(43.6)%

Ordinary profit

2,013

1,200(40.4)%

Profit attributable toowners of parent

1,736900(48.2)%

JPY 71.13

JPY 36.84---Basic earnings per share
Exchange Rate(average duringperiod)

US Dollar

106.06112.00Euro

121.81130.00(unit: JPY)

Singapore Dollar

77.65

83.00

9

Topics-Received the "Good Design Award 2021” for two products. (Cell freezing bag, Feeding Bag)
October 2021

Cell freezing bag CellQua®
GOOD DESIGN BEST100Feeding Bag-Launched new product “PECOGINA”, Tongue muscle training device.
October 2021

PECOGINA starters kit-Launched an alcohol for disinfection “MEDICLEAN” to Medical institutions.
December 2021

MEDICLEAN

10

The Bridge to Good Health Care

The assessment figures described on this report are based on available information
at this moment, including uncertain data. Actual results may be different from the figures.

11